Chronic Hyperinsulinemia Does Not Increase the Production Rate of High-Density Lipoprotein Apolipoprotein AI Evidence From a Kinetic Study in Patients With Insulinoma

被引:4
|
作者
Duvillard, Laurence [1 ,2 ]
Florentin, Emmanuel [1 ,2 ]
Pont, Frederic [1 ]
Petit, Jean-Michel [1 ,3 ]
Baillot-Rudoni, Sabine [3 ]
Penfornis, Alfred [4 ]
Verges, Bruno [1 ,3 ]
机构
[1] Univ Bourgogne, INSERM, U866, Fac Med, Dijon, France
[2] CHU, Lab Biol Med, Dijon, France
[3] CHU, Serv Endocrinol & Malad Metab, Dijon, France
[4] CHU Besancon, Serv Endocrinol & Malad Metab, F-25030 Besancon, France
关键词
apolipoprotein AI; hyperinsulinism; insulinoma; kinetics; metabolic X syndrome; IN-VIVO EVIDENCE; HDL-APOA-I; METABOLISM; ADIPONECTIN; CLEARANCE; GLUCOSE; PLASMA; OBESE;
D O I
10.1161/ATVBAHA.113.301597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective In vitro studies showed that insulin stimulates the production of apolipoprotein AI (apoAI). Thus, we hypothesized that chronic hyperinsulinemia could contribute to the increase in the production of high-density lipoprotein apoAI that is observed in metabolic syndrome. Approach and Results We performed an in vivo kinetic study with stable isotope in 7 patients with insulinoma who showed hyperinsulinemia but no insulin resistance, 8 patients with insulin resistance, and 16 controls. Insulinemia was 3.1x (P<0.01) higher in patients with insulinoma or insulin resistance than in controls in the fasting state and, respectively, 3.5x and 2.6x (P<0.05) higher in the fed state. The high-density lipoprotein apoAI pool size was smaller in patients with insulin resistance than in controls (49.35.4 versus 59.6 +/- 7.7 mgkg(-1); P<0.01), whereas both the high-density lipoprotein apoAI fractional catabolic rate and the high-density lipoprotein apoAI production rate were higher (0.30 +/- 0.07 versus 0.20 +/- 0.04 poold(-1); P<0.0001 and 14.6 +/- 1.5 versus 11.5 +/- 1.9 mgkg(-1)d(-1); P<0.01, respectively). In contrast, no significant difference was observed for these parameters between patients with insulinoma and controls. In patients with insulinoma, the apoAI pool size tended to be greater than in patients with insulin resistance (56.3 +/- 8.6 versus 49.3 +/- 5.4 mgkg(-1); P=0.078), whereas both the apoAI fractional catabolic rate and the production rate were lower (0.20 +/- 0.06 versus 0.30 +/- 0.07 poold(-1); P<0.01 and 11.1 +/- 1.6 versus 14.6 +/- 1.5 mgkg(-1)d(-1); P<0.01, respectively). The apoAI fractional catabolic rate was the only variable associated with the apoAI production rate in multivariate analysis and explained 80% of its variance. Conclusions Chronic endogenous hyperinsulinemia does not induce any increase in the apoAI production rate, which seems to be more dependent on the apoAI fractional catabolic rate.
引用
收藏
页码:2460 / 2465
页数:6
相关论文
共 8 条
  • [1] Endogenous Chronic Hyperinsulinemia Does Not Increase the Production Rate of VLDL Apolipoprotein B: Proof from a Kinetic Study in Patients with Insulinoma
    Duvillard, Laurence
    Florentin, Emmanuel
    Pont, Frederic
    Petit, Jean-Michel
    Baillot-Rudoni, Sabine
    Penfornis, Alfred
    Verges, Bruno
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (07) : 2163 - 2170
  • [2] High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients.: An in vivo stable isotope study
    Pont, F
    Duvillard, L
    Florentin, E
    Gambert, P
    Vergès, B
    INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 (09) : 1151 - 1158
  • [3] High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study
    F Pont
    L Duvillard
    E Florentin
    P Gambert
    B Vergès
    International Journal of Obesity, 2002, 26 : 1151 - 1158
  • [4] The relationship between serum amyloid A and apolipoprotein A-I in high-density lipoprotein isolated from patients with coronary heart disease
    Wang Dong-xue
    Liu Hong
    Yan Li-rong
    Zhang Ye-ping
    Guan Xiao-yuan
    Xu Zhi-min
    Jia You-hong
    Li Yi-shi
    CHINESE MEDICAL JOURNAL, 2013, 126 (19) : 3656 - 3661
  • [5] Association of non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus: Evidence from the ACCORD cohort
    Liu, Maojun
    Pei, Junyu
    Zeng, Cheng
    Xin, Ying
    Zhang, Yifeng
    Tang, Peiqi
    Deng, Simin
    Hu, Xinqun
    DIABETES OBESITY & METABOLISM, 2025, 27 (01) : 300 - 311
  • [6] High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study
    Elbaz, Meyer
    Faccini, Julien
    Bongard, Vanina
    Ingueneau, Cecile
    Taraszkiewicz, Dorotea
    Perret, Bertrand
    Ferrieres, Jean
    Ruidavets, Jean-Bernard
    Vindis, Cecile
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2016, 109 (11) : 607 - 617
  • [7] High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate
    Brinck, Jonas W.
    Thomas, Aurelien
    Brulhart-Meynet, Marie-Claude
    Lauer, Estelle
    Frej, Cecilia
    Dahlback, Bjorn
    Stenvinkel, Peter
    James, Richard W.
    Frias, Miguel A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2018, 48 (02)
  • [8] De Novo Leukotriene B4 Production From High-Density Lipoprotein (HDL) in Recurrent Cardiovascular Disease Patients Deteriorates Anti-Inflammatory Properties of HDL
    Tsuda, Shigeyasu
    Shinohara, Masakazu
    Oshita, Toshihiko
    Nagao, Manabu
    Tanaka, Nobuaki
    Mori, Takeshige
    Hara, Tetsuya
    Irino, Yasuhiro
    Toh, Ryuji
    Ishida, Tatsuro
    Hirata, Ken-ichi
    CIRCULATION, 2016, 134